Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis
Differences in immunogenicity between mRNA SARS-CoV-2 vaccines have not been well characterized in patients undergoing dialysis. We compared the serologic response in patients undergoing maintenance hemodialysis after vaccination against SARS-CoV-2 with BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Mode...
Gespeichert in:
| Veröffentlicht in: | Canadian Medical Association journal (CMAJ) 2022-02, Vol.194 (8), p.E297-E305 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | E305 |
|---|---|
| container_issue | 8 |
| container_start_page | E297 |
| container_title | Canadian Medical Association journal (CMAJ) |
| container_volume | 194 |
| creator | Yau, Kevin Chan, Christopher T Abe, Kento T Jiang, Yidi Atiquzzaman, Mohammad Mullin, Sarah I Shadowitz, Ellen Liu, Lisa Kostadinovic, Ema Sukovic, Tatjana Gonzalez, Anny McGrath-Chong, Margaret E Oliver, Matthew J Perl, Jeffrey Leis, Jerome A Bolotin, Shelly Tran, Vanessa Levin, Adeera Blake, Peter G Colwill, Karen Gingras, Anne-Claude Hladunewich, Michelle A |
| description | Differences in immunogenicity between mRNA SARS-CoV-2 vaccines have not been well characterized in patients undergoing dialysis. We compared the serologic response in patients undergoing maintenance hemodialysis after vaccination against SARS-CoV-2 with BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna).
We conducted a prospective observational cohort study at 2 academic centres in Toronto, Canada, from Feb. 2, 2021, to July 20, 2021, which included 129 and 95 patients who received the BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines, respectively. We measured SARS-CoV-2 immunoglobulin G antibodies to the spike protein (anti-spike), receptor binding domain (anti-RBD) and nucleocapsid protein (anti-NP) at 6-7 and 12 weeks after the second dose of vaccine and compared those levels with the median convalescent serum antibody levels from 211 controls who were previously infected with SARS-CoV-2.
At 6-7 weeks after 2-dose vaccination, we found that 51 of 70 patients (73%) who received BNT162b2 and 83 of 87 (95%) who received mRNA-1273 attained convalescent levels of anti-spike antibody (
< 0.001). In those who received BNT162b2, 35 of 70 (50%) reached the convalescent level for anti-RBD compared with 69 of 87 (79%) who received mRNA-1273 (
< 0.001). At 12 weeks after the second dose, anti-spike and anti-RBD levels were significantly lower in patients who received BNT162b2 than in those who received mRNA-1273. For anti-spike, 70 of 122 patients (57.4%) who received BNT162b2 maintained the convalescent level versus 68 of 71 (96%) of those who received mRNA-1273 (
< 0.001). For anti-RBD, 47 of 122 patients (38.5%) who received BNT162b2 maintained the anti-RBD convalescent level versus 45 of 71 (63%) of those who received mRNA-1273 (
= 0.002).
In patients undergoing hemodialysis, mRNA-1273 elicited a stronger humoral response than BNT162b2. Given the rapid decline in immunogenicity at 12 weeks in patients who received BNT162b2, a third dose is recommended in patients undergoing dialysis as a primary series, similar to recommendations for other vulnerable populations. |
| doi_str_mv | 10.1503/CMAJ.211881 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9053976</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2637408472</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-bb5a9e51881c3ba749f370855fb44945dbe3ff5f1ed64b0815a0d08902a6f6263</originalsourceid><addsrcrecordid>eNpdkU9vEzEQxS1ERUPhxB1Z4pKqcvHfXfuClIbSgtqA2sDV8nrt1NGuHda7lcIH4HOzUdoK8GUkz09v3swD4A3Bp0Rg9n5-PftySgmRkjwDE8KlRJRR9RxMsKQYMcWLQ_Ay5zUeH6PlC3DIBCGClWICfn8M3rvOResyDBG2N4sZIrRkcHqdatdFcwxNrOHZYkkKWlE4_ebDL9ehs5AWS2fvjuHt7OYWzdMPROG9sTZEB0PbDjGtXAw29Fto2hRXcGP64GKf4RBH4VUK418dTLPNIb8CB9402b1-qEfg-6fz5fwSXX29-DyfXSHLsepRVQmjnNitalllSq48K7EUwlecKy7qyjHvhSeuLniFJREG11gqTE3hC1qwI_Bhr7sZqtbVdvTTmUZvutCabquTCfrfTgx3epXutcKCqXInMH0Q6NLPweVetyFb1zQmujRkTccpGAtF5Ii--w9dp2E8aLOjWMmx5CUdqZM9ZbuUc-f8kxmC9S5fbVuz1vt8R_rt3_6f2MdA2R-rx58c</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2637408472</pqid></control><display><type>article</type><title>Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Yau, Kevin ; Chan, Christopher T ; Abe, Kento T ; Jiang, Yidi ; Atiquzzaman, Mohammad ; Mullin, Sarah I ; Shadowitz, Ellen ; Liu, Lisa ; Kostadinovic, Ema ; Sukovic, Tatjana ; Gonzalez, Anny ; McGrath-Chong, Margaret E ; Oliver, Matthew J ; Perl, Jeffrey ; Leis, Jerome A ; Bolotin, Shelly ; Tran, Vanessa ; Levin, Adeera ; Blake, Peter G ; Colwill, Karen ; Gingras, Anne-Claude ; Hladunewich, Michelle A</creator><creatorcontrib>Yau, Kevin ; Chan, Christopher T ; Abe, Kento T ; Jiang, Yidi ; Atiquzzaman, Mohammad ; Mullin, Sarah I ; Shadowitz, Ellen ; Liu, Lisa ; Kostadinovic, Ema ; Sukovic, Tatjana ; Gonzalez, Anny ; McGrath-Chong, Margaret E ; Oliver, Matthew J ; Perl, Jeffrey ; Leis, Jerome A ; Bolotin, Shelly ; Tran, Vanessa ; Levin, Adeera ; Blake, Peter G ; Colwill, Karen ; Gingras, Anne-Claude ; Hladunewich, Michelle A</creatorcontrib><description>Differences in immunogenicity between mRNA SARS-CoV-2 vaccines have not been well characterized in patients undergoing dialysis. We compared the serologic response in patients undergoing maintenance hemodialysis after vaccination against SARS-CoV-2 with BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna).
We conducted a prospective observational cohort study at 2 academic centres in Toronto, Canada, from Feb. 2, 2021, to July 20, 2021, which included 129 and 95 patients who received the BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines, respectively. We measured SARS-CoV-2 immunoglobulin G antibodies to the spike protein (anti-spike), receptor binding domain (anti-RBD) and nucleocapsid protein (anti-NP) at 6-7 and 12 weeks after the second dose of vaccine and compared those levels with the median convalescent serum antibody levels from 211 controls who were previously infected with SARS-CoV-2.
At 6-7 weeks after 2-dose vaccination, we found that 51 of 70 patients (73%) who received BNT162b2 and 83 of 87 (95%) who received mRNA-1273 attained convalescent levels of anti-spike antibody (
< 0.001). In those who received BNT162b2, 35 of 70 (50%) reached the convalescent level for anti-RBD compared with 69 of 87 (79%) who received mRNA-1273 (
< 0.001). At 12 weeks after the second dose, anti-spike and anti-RBD levels were significantly lower in patients who received BNT162b2 than in those who received mRNA-1273. For anti-spike, 70 of 122 patients (57.4%) who received BNT162b2 maintained the convalescent level versus 68 of 71 (96%) of those who received mRNA-1273 (
< 0.001). For anti-RBD, 47 of 122 patients (38.5%) who received BNT162b2 maintained the anti-RBD convalescent level versus 45 of 71 (63%) of those who received mRNA-1273 (
= 0.002).
In patients undergoing hemodialysis, mRNA-1273 elicited a stronger humoral response than BNT162b2. Given the rapid decline in immunogenicity at 12 weeks in patients who received BNT162b2, a third dose is recommended in patients undergoing dialysis as a primary series, similar to recommendations for other vulnerable populations.</description><identifier>ISSN: 0820-3946</identifier><identifier>EISSN: 1488-2329</identifier><identifier>DOI: 10.1503/CMAJ.211881</identifier><identifier>PMID: 35115375</identifier><language>eng</language><publisher>Canada: CMA Impact, Inc</publisher><subject>2019-nCoV Vaccine mRNA-1273 ; Aged ; Antibodies ; BNT162 Vaccine ; Cardiovascular disease ; Coronaviruses ; COVID-19 - immunology ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - immunology ; Drug dosages ; Female ; Generalized linear models ; Health care networks ; Health sciences ; Hemodialysis ; Humans ; Immunization ; Immunogenicity, Vaccine ; Immunoglobulins ; Kidney diseases ; Linear Models ; Male ; Middle Aged ; Mortality ; Ontario ; Population ; Prospective Studies ; Proteins ; Renal Dialysis ; SARS-CoV-2 - immunology ; Serology ; Severe acute respiratory syndrome coronavirus 2 ; Vaccination</subject><ispartof>Canadian Medical Association journal (CMAJ), 2022-02, Vol.194 (8), p.E297-E305</ispartof><rights>2022 CMA Impact Inc. or its licensors.</rights><rights>Copyright Joule Inc Feb 28, 2022</rights><rights>2022 CMA Impact Inc. or its licensors 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-bb5a9e51881c3ba749f370855fb44945dbe3ff5f1ed64b0815a0d08902a6f6263</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053976/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053976/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35115375$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yau, Kevin</creatorcontrib><creatorcontrib>Chan, Christopher T</creatorcontrib><creatorcontrib>Abe, Kento T</creatorcontrib><creatorcontrib>Jiang, Yidi</creatorcontrib><creatorcontrib>Atiquzzaman, Mohammad</creatorcontrib><creatorcontrib>Mullin, Sarah I</creatorcontrib><creatorcontrib>Shadowitz, Ellen</creatorcontrib><creatorcontrib>Liu, Lisa</creatorcontrib><creatorcontrib>Kostadinovic, Ema</creatorcontrib><creatorcontrib>Sukovic, Tatjana</creatorcontrib><creatorcontrib>Gonzalez, Anny</creatorcontrib><creatorcontrib>McGrath-Chong, Margaret E</creatorcontrib><creatorcontrib>Oliver, Matthew J</creatorcontrib><creatorcontrib>Perl, Jeffrey</creatorcontrib><creatorcontrib>Leis, Jerome A</creatorcontrib><creatorcontrib>Bolotin, Shelly</creatorcontrib><creatorcontrib>Tran, Vanessa</creatorcontrib><creatorcontrib>Levin, Adeera</creatorcontrib><creatorcontrib>Blake, Peter G</creatorcontrib><creatorcontrib>Colwill, Karen</creatorcontrib><creatorcontrib>Gingras, Anne-Claude</creatorcontrib><creatorcontrib>Hladunewich, Michelle A</creatorcontrib><title>Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis</title><title>Canadian Medical Association journal (CMAJ)</title><addtitle>CMAJ</addtitle><description>Differences in immunogenicity between mRNA SARS-CoV-2 vaccines have not been well characterized in patients undergoing dialysis. We compared the serologic response in patients undergoing maintenance hemodialysis after vaccination against SARS-CoV-2 with BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna).
We conducted a prospective observational cohort study at 2 academic centres in Toronto, Canada, from Feb. 2, 2021, to July 20, 2021, which included 129 and 95 patients who received the BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines, respectively. We measured SARS-CoV-2 immunoglobulin G antibodies to the spike protein (anti-spike), receptor binding domain (anti-RBD) and nucleocapsid protein (anti-NP) at 6-7 and 12 weeks after the second dose of vaccine and compared those levels with the median convalescent serum antibody levels from 211 controls who were previously infected with SARS-CoV-2.
At 6-7 weeks after 2-dose vaccination, we found that 51 of 70 patients (73%) who received BNT162b2 and 83 of 87 (95%) who received mRNA-1273 attained convalescent levels of anti-spike antibody (
< 0.001). In those who received BNT162b2, 35 of 70 (50%) reached the convalescent level for anti-RBD compared with 69 of 87 (79%) who received mRNA-1273 (
< 0.001). At 12 weeks after the second dose, anti-spike and anti-RBD levels were significantly lower in patients who received BNT162b2 than in those who received mRNA-1273. For anti-spike, 70 of 122 patients (57.4%) who received BNT162b2 maintained the convalescent level versus 68 of 71 (96%) of those who received mRNA-1273 (
< 0.001). For anti-RBD, 47 of 122 patients (38.5%) who received BNT162b2 maintained the anti-RBD convalescent level versus 45 of 71 (63%) of those who received mRNA-1273 (
= 0.002).
In patients undergoing hemodialysis, mRNA-1273 elicited a stronger humoral response than BNT162b2. Given the rapid decline in immunogenicity at 12 weeks in patients who received BNT162b2, a third dose is recommended in patients undergoing dialysis as a primary series, similar to recommendations for other vulnerable populations.</description><subject>2019-nCoV Vaccine mRNA-1273</subject><subject>Aged</subject><subject>Antibodies</subject><subject>BNT162 Vaccine</subject><subject>Cardiovascular disease</subject><subject>Coronaviruses</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - immunology</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Generalized linear models</subject><subject>Health care networks</subject><subject>Health sciences</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunogenicity, Vaccine</subject><subject>Immunoglobulins</subject><subject>Kidney diseases</subject><subject>Linear Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Ontario</subject><subject>Population</subject><subject>Prospective Studies</subject><subject>Proteins</subject><subject>Renal Dialysis</subject><subject>SARS-CoV-2 - immunology</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccination</subject><issn>0820-3946</issn><issn>1488-2329</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU9vEzEQxS1ERUPhxB1Z4pKqcvHfXfuClIbSgtqA2sDV8nrt1NGuHda7lcIH4HOzUdoK8GUkz09v3swD4A3Bp0Rg9n5-PftySgmRkjwDE8KlRJRR9RxMsKQYMcWLQ_Ay5zUeH6PlC3DIBCGClWICfn8M3rvOResyDBG2N4sZIrRkcHqdatdFcwxNrOHZYkkKWlE4_ebDL9ehs5AWS2fvjuHt7OYWzdMPROG9sTZEB0PbDjGtXAw29Fto2hRXcGP64GKf4RBH4VUK418dTLPNIb8CB9402b1-qEfg-6fz5fwSXX29-DyfXSHLsepRVQmjnNitalllSq48K7EUwlecKy7qyjHvhSeuLniFJREG11gqTE3hC1qwI_Bhr7sZqtbVdvTTmUZvutCabquTCfrfTgx3epXutcKCqXInMH0Q6NLPweVetyFb1zQmujRkTccpGAtF5Ii--w9dp2E8aLOjWMmx5CUdqZM9ZbuUc-f8kxmC9S5fbVuz1vt8R_rt3_6f2MdA2R-rx58c</recordid><startdate>20220228</startdate><enddate>20220228</enddate><creator>Yau, Kevin</creator><creator>Chan, Christopher T</creator><creator>Abe, Kento T</creator><creator>Jiang, Yidi</creator><creator>Atiquzzaman, Mohammad</creator><creator>Mullin, Sarah I</creator><creator>Shadowitz, Ellen</creator><creator>Liu, Lisa</creator><creator>Kostadinovic, Ema</creator><creator>Sukovic, Tatjana</creator><creator>Gonzalez, Anny</creator><creator>McGrath-Chong, Margaret E</creator><creator>Oliver, Matthew J</creator><creator>Perl, Jeffrey</creator><creator>Leis, Jerome A</creator><creator>Bolotin, Shelly</creator><creator>Tran, Vanessa</creator><creator>Levin, Adeera</creator><creator>Blake, Peter G</creator><creator>Colwill, Karen</creator><creator>Gingras, Anne-Claude</creator><creator>Hladunewich, Michelle A</creator><general>CMA Impact, Inc</general><general>CMA Impact Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M3G</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220228</creationdate><title>Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis</title><author>Yau, Kevin ; Chan, Christopher T ; Abe, Kento T ; Jiang, Yidi ; Atiquzzaman, Mohammad ; Mullin, Sarah I ; Shadowitz, Ellen ; Liu, Lisa ; Kostadinovic, Ema ; Sukovic, Tatjana ; Gonzalez, Anny ; McGrath-Chong, Margaret E ; Oliver, Matthew J ; Perl, Jeffrey ; Leis, Jerome A ; Bolotin, Shelly ; Tran, Vanessa ; Levin, Adeera ; Blake, Peter G ; Colwill, Karen ; Gingras, Anne-Claude ; Hladunewich, Michelle A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-bb5a9e51881c3ba749f370855fb44945dbe3ff5f1ed64b0815a0d08902a6f6263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>2019-nCoV Vaccine mRNA-1273</topic><topic>Aged</topic><topic>Antibodies</topic><topic>BNT162 Vaccine</topic><topic>Cardiovascular disease</topic><topic>Coronaviruses</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - immunology</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Generalized linear models</topic><topic>Health care networks</topic><topic>Health sciences</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunogenicity, Vaccine</topic><topic>Immunoglobulins</topic><topic>Kidney diseases</topic><topic>Linear Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Ontario</topic><topic>Population</topic><topic>Prospective Studies</topic><topic>Proteins</topic><topic>Renal Dialysis</topic><topic>SARS-CoV-2 - immunology</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yau, Kevin</creatorcontrib><creatorcontrib>Chan, Christopher T</creatorcontrib><creatorcontrib>Abe, Kento T</creatorcontrib><creatorcontrib>Jiang, Yidi</creatorcontrib><creatorcontrib>Atiquzzaman, Mohammad</creatorcontrib><creatorcontrib>Mullin, Sarah I</creatorcontrib><creatorcontrib>Shadowitz, Ellen</creatorcontrib><creatorcontrib>Liu, Lisa</creatorcontrib><creatorcontrib>Kostadinovic, Ema</creatorcontrib><creatorcontrib>Sukovic, Tatjana</creatorcontrib><creatorcontrib>Gonzalez, Anny</creatorcontrib><creatorcontrib>McGrath-Chong, Margaret E</creatorcontrib><creatorcontrib>Oliver, Matthew J</creatorcontrib><creatorcontrib>Perl, Jeffrey</creatorcontrib><creatorcontrib>Leis, Jerome A</creatorcontrib><creatorcontrib>Bolotin, Shelly</creatorcontrib><creatorcontrib>Tran, Vanessa</creatorcontrib><creatorcontrib>Levin, Adeera</creatorcontrib><creatorcontrib>Blake, Peter G</creatorcontrib><creatorcontrib>Colwill, Karen</creatorcontrib><creatorcontrib>Gingras, Anne-Claude</creatorcontrib><creatorcontrib>Hladunewich, Michelle A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database (ProQuest)</collection><collection>CBCA Reference & Current Events</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Canadian Medical Association journal (CMAJ)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yau, Kevin</au><au>Chan, Christopher T</au><au>Abe, Kento T</au><au>Jiang, Yidi</au><au>Atiquzzaman, Mohammad</au><au>Mullin, Sarah I</au><au>Shadowitz, Ellen</au><au>Liu, Lisa</au><au>Kostadinovic, Ema</au><au>Sukovic, Tatjana</au><au>Gonzalez, Anny</au><au>McGrath-Chong, Margaret E</au><au>Oliver, Matthew J</au><au>Perl, Jeffrey</au><au>Leis, Jerome A</au><au>Bolotin, Shelly</au><au>Tran, Vanessa</au><au>Levin, Adeera</au><au>Blake, Peter G</au><au>Colwill, Karen</au><au>Gingras, Anne-Claude</au><au>Hladunewich, Michelle A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis</atitle><jtitle>Canadian Medical Association journal (CMAJ)</jtitle><addtitle>CMAJ</addtitle><date>2022-02-28</date><risdate>2022</risdate><volume>194</volume><issue>8</issue><spage>E297</spage><epage>E305</epage><pages>E297-E305</pages><issn>0820-3946</issn><eissn>1488-2329</eissn><abstract>Differences in immunogenicity between mRNA SARS-CoV-2 vaccines have not been well characterized in patients undergoing dialysis. We compared the serologic response in patients undergoing maintenance hemodialysis after vaccination against SARS-CoV-2 with BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna).
We conducted a prospective observational cohort study at 2 academic centres in Toronto, Canada, from Feb. 2, 2021, to July 20, 2021, which included 129 and 95 patients who received the BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines, respectively. We measured SARS-CoV-2 immunoglobulin G antibodies to the spike protein (anti-spike), receptor binding domain (anti-RBD) and nucleocapsid protein (anti-NP) at 6-7 and 12 weeks after the second dose of vaccine and compared those levels with the median convalescent serum antibody levels from 211 controls who were previously infected with SARS-CoV-2.
At 6-7 weeks after 2-dose vaccination, we found that 51 of 70 patients (73%) who received BNT162b2 and 83 of 87 (95%) who received mRNA-1273 attained convalescent levels of anti-spike antibody (
< 0.001). In those who received BNT162b2, 35 of 70 (50%) reached the convalescent level for anti-RBD compared with 69 of 87 (79%) who received mRNA-1273 (
< 0.001). At 12 weeks after the second dose, anti-spike and anti-RBD levels were significantly lower in patients who received BNT162b2 than in those who received mRNA-1273. For anti-spike, 70 of 122 patients (57.4%) who received BNT162b2 maintained the convalescent level versus 68 of 71 (96%) of those who received mRNA-1273 (
< 0.001). For anti-RBD, 47 of 122 patients (38.5%) who received BNT162b2 maintained the anti-RBD convalescent level versus 45 of 71 (63%) of those who received mRNA-1273 (
= 0.002).
In patients undergoing hemodialysis, mRNA-1273 elicited a stronger humoral response than BNT162b2. Given the rapid decline in immunogenicity at 12 weeks in patients who received BNT162b2, a third dose is recommended in patients undergoing dialysis as a primary series, similar to recommendations for other vulnerable populations.</abstract><cop>Canada</cop><pub>CMA Impact, Inc</pub><pmid>35115375</pmid><doi>10.1503/CMAJ.211881</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0820-3946 |
| ispartof | Canadian Medical Association journal (CMAJ), 2022-02, Vol.194 (8), p.E297-E305 |
| issn | 0820-3946 1488-2329 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9053976 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | 2019-nCoV Vaccine mRNA-1273 Aged Antibodies BNT162 Vaccine Cardiovascular disease Coronaviruses COVID-19 - immunology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - immunology Drug dosages Female Generalized linear models Health care networks Health sciences Hemodialysis Humans Immunization Immunogenicity, Vaccine Immunoglobulins Kidney diseases Linear Models Male Middle Aged Mortality Ontario Population Prospective Studies Proteins Renal Dialysis SARS-CoV-2 - immunology Serology Severe acute respiratory syndrome coronavirus 2 Vaccination |
| title | Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T13%3A48%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differences%20in%20mRNA-1273%20(Moderna)%20and%20BNT162b2%20(Pfizer-BioNTech)%20SARS-CoV-2%20vaccine%20immunogenicity%20among%20patients%20undergoing%20dialysis&rft.jtitle=Canadian%20Medical%20Association%20journal%20(CMAJ)&rft.au=Yau,%20Kevin&rft.date=2022-02-28&rft.volume=194&rft.issue=8&rft.spage=E297&rft.epage=E305&rft.pages=E297-E305&rft.issn=0820-3946&rft.eissn=1488-2329&rft_id=info:doi/10.1503/CMAJ.211881&rft_dat=%3Cproquest_pubme%3E2637408472%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2637408472&rft_id=info:pmid/35115375&rfr_iscdi=true |